NEW YORK, Aug. 17, 2018 (GLOBE NEWSWIRE) -- The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
Mercury Systems, Inc. (NASDAQGS: MRCY) Class Period: October 24, 2017 to April 24, 2018 Lead Plaintiff Deadline: September 10, 2018
Throughout the class period, Mercury Systems, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) Mercury’s decision to in-source processing was adversely impacting Mercury’s operating margins and free cash-flow generation and conversion; (ii) Mercury’s model was becoming structurally more working capital intensive; (iii) as a result of the foregoing, Mercury’s public statements were materially false and misleading at all relevant times.
Get additional information about the MRCY lawsuit: http://www.kleinstocklaw.com/pslra-c/mercury-systems?wire=3
PolarityTE, Inc. (NASDAQ: COOL) Class Period: March 31, 2017 to June 22, 2018 Lead Plaintiff Deadline: August 27, 2018
PolarityTE, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose the true nature of (i) the status of Patent #14/954,335 at the time it was acquired by the Company on April 7, 2017 and the months following; (ii) the updated status of Patent #14/954,335 after its June 4, 2018 final rejection by the United States Patent Office; and (iii) that as a result of the foregoing, PolarityTE's publicly disseminated financial statements were materially false and misleading.
Get additional information about the COOL lawsuit: http://www.kleinstocklaw.com/pslra-c/polarityte-inc?wire=3
Restoration Robotics, Inc. (NASDAQGM: HAIR) Class Period: Pursuant to the IPO between October 12, 2017 and October 16, 2017 Lead Plaintiff Deadline: August 21, 2018
The complaint alleges that Restoration Robotics negligently issued untrue statements of material facts in, and omitted to state material facts required to be stated from, the Offering Materials issued in connection with the Initial Public Offering. The complaint further alleges that as a result of the materially misleading Offering Materials, the Company’s stock price was artificially inflated at the time of the IPO.
Get additional information about the HAIR lawsuit: http://www.kleinstocklaw.com/pslra-c/restorat...air?wire=3
Newell Brands Inc. (NYSE: NWL) Class Period: February 6, 2017 to January 24, 2018 Lead Plaintiff Deadline: August 20, 2018
The lawsuit alleges that throughout the class period, Newell Brands Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the Company’s retail channel was loaded with extremely high levels of unsold Newell product; (ii) contrary to defendants’ representations, the build-up of Newell inventory in the retail channel was due to Company-specific rather than macroeconomic reasons; (iii) as a result of the unusually high levels of unsold inventory in the retail channel, Newell was exposed to a heightened risk that it would experience slower sales growth in future periods; and (iv) undisclosed managerial and cultural differences in the legacy Newell and Jarden businesses had created significant discord that was having a material adverse effect on the Company’s operating performance.
Get additional information about the NWL lawsuit: http://www.kleinstocklaw.com/pslra-c/newell-b...inc?wire=3
Flex Pharma, Inc. (NASDAQ: FLKS) Class Period: November 6, 2017 to June 12, 2018 Lead Plaintiff Deadline: August 20, 2018
Throughout the class period, Flex Pharma, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) the Company overstated the viability and approval prospects for its product candidate FLX-787 for the treatment of amyotrophic lateral sclerosis and Charcot-Marie-Tooth disease; and (ii) as a result, Flex's public statements were materially false and misleading at all relevant times.
On June 13, 2018, Flex announced that it planned to halt its FLX-787 trials, citing oral tolerability concerns observed in both studies. Flex also said that it will restructure its organization to reduce costs, including reducing its workforce by approximately 60%, and that Flex's Board is exploring "strategic alternatives, including the potential sale or merger of the company." Following this news, Flex stock dropped $3.14 per share, or 75.12%, to close at $1.04 on June 13, 2018.
Get additional information about the FLKS lawsuit: http://www.kleinstocklaw.com/pslra-c/flex-pharma-inc?wire=3
Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. There is no cost or obligation to you. If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
Joseph Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Joseph Klein, Esq. Empire State Building 350 Fifth Avenue 59th Floor New York, NY 10118 jk@kleinstocklaw.com Telephone: (212) 616-4899 Fax: (347) 558-9665 www.kleinstocklaw.com
